AMFI Registered MFD · ARN-130934 · Mutual fund investments are subject to market risks. CA Amit Kumar Jain · +91 93522 44475 Poornima Jain · +91 92525 44475 support@plenitude.co.in हिंदी

Procter & Gamble Health Limited share price

Procter & Gamble Health Limited manufactures and markets pharmaceutical and chemical products in India and internationally. It offers over-the-counter products, vitamins, minerals, and supplements under the Betamil, Polybion, Cosome, Evion, Neurobion, Seven Seas, Nasivion, and Livogen brand names. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. The company operates as a subsidiary of Procter & Gamble Overseas India B.V.Read more

WebsiteNSEBSE

HealthcareDrug Manufacturers - Specialty & GenericNifty Microcap 250NSE: PGHLISIN INE199A01012
16 Oct 2026, 3:29 PM IST₹5,200.00▲ 51.00 (0.99%)
  • Market Cap₹ 8,632 Cr.
  • Current Price₹ 5,200.00
  • High / Low₹ 6,975 / 4,707
  • Stock P/E24.2
  • Book Value₹ 316
  • Dividend Yield3.01 %
  • ROCE76.8 %
  • ROE61.50 %
  • Face Value₹ 10.0
More figures (10)
  • EPS (TTM)₹ 215.19
  • Price / Book16.46
  • OPM31.4 %
  • Debt / Equity0.02
  • Sales growth (3Y)8.2 %
  • Profit growth (3Y)19.3 %
  • Promoter holding52.2 %
  • EV / EBITDA27.3
  • Beta0.18
  • All-time high₹ 7,500

Price chart

Returns1M3M6MYTD1Y3Y CAGR5Y CAGR
PGHL-4.76%-24.14%+4.05%-8.82%-17.26%+0.21%-1.35%
Nifty 50-0.31%-3.85%-4.34%-11.42%-9.53%+5.46%+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

  • Procter & Gamble Health Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹8,632 crore.
  • It trades at 24.2 times its last 12 months' earnings and 16.5 times book value.
  • Revenue grew 8.2% a year over the last 3 years, profit 19.3% a year.
  • Return on equity was 61.5% and return on capital employed 76.8% in the latest year.
  • Debt was 0.02 times shareholders' equity.
  • The share price is 25.5% below its 52-week high and down 17.3% over one year.
  • Promoters and insiders hold about 52.2%; institutions about 14.8%.

Pros

  • Strong return on equity: 42.1% on average over the last 3 years.
  • Company is almost debt-free (debt is 0.02 times equity).
  • Trades at 24.2 times earnings, below its 3-year median of 35.3.
  • Pays a healthy dividend: about 104% of profit last year.

Cons

  • Trades at 16.5 times its book value.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Procter & Gamble Health Limited

Procter & Gamble Health Limited manufactures and markets pharmaceutical and chemical products in India and internationally. It offers over-the-counter products, vitamins, minerals, and supplements under the Betamil, Polybion, Cosome, Evion, Neurobion, Seven Seas, Nasivion, and Livogen brand names. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. The company operates as a subsidiary of Procter & Gamble Overseas India B.V.

Employees
1,276
Head office
Mumbai
NSE industry
Healthcare

Peer comparison

CompanyMarket cap (₹ Cr)P/EP/BROEOPMSales CAGRDiv. yield
Procter & Gamble Health LimitedPGHL8,63224.216.4661.5%31.4%+8.2%3.01%
Sun Pharmaceutical Industries LimitedSUNPHARMA4,21,99534.95.0514.7%23.4%+10.4%0.91%
Divi's Laboratories LimitedDIVISLAB2,42,75883.014.4816.2%28.4%+11.0%0.33%
Torrent Pharmaceuticals LimitedTORNTPHARM1,73,40672.818.3927.1%25.0%+13.3%0.83%
Zydus Lifesciences LimitedZYDUSLIFE1,12,02025.04.1719.7%21.7%+16.5%0.09%
Cipla LimitedCIPLA1,07,05131.83.1111.8%17.5%+7.2%0.98%
Dr. Reddy's Laboratories LimitedDRREDDY1,02,70731.02.6812.1%14.9%+11.0%0.66%
Abbott India LimitedABBOTINDIA55,60934.411.6534.5%26.3%+9.0%2.01%
Ajanta Pharma LimitedAJANTPHARM41,59936.79.1925.4%24.5%+13.4%1.91%
Venus Remedies LimitedVENUSREM2,20919.03.3216.8%14.5%+9.9%0.64%

Companies in the same industry (Drug Manufacturers - Specialty & Generic). Tap a heading to sort. Sorting is a way to explore data, not a recommendation.

Quarterly Results

Standalone figures in ₹ crore

₹ CrJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
301305310252284313310311339325374370364
256216208185236199186230248205263235264
Operating Profit458910267481141238190120110136100
OPM %15%29%33%27%17%36%40%26%27%37%30%37%27%
5652234345444
Interest0000000000000
Depreciation6677766556666
Profit before tax448810063231111227989119109133129
32%26%28%26%27%26%25%22%25%26%29%29%26%
30667247178291616689789596
EPS in Rs17.9639.5043.4028.0010.1149.6054.7636.8639.8753.3446.7456.9957.92
Raw filing

Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Standalone figures in ₹ crore

₹ CrMar 2025Mar 2026TTM
9341,4081,433
616951967
Operating Profit318457466
OPM %34%32%33%
101717
Interest011
Depreciation172424
Profit before tax312450490
25%27%27%
234327357
EPS in Rs141.22196.94214.99
Dividend Payout %104%

Compounded Sales Growth

TTM:
13%

Compounded Profit Growth

TTM:
19%

Stock Price CAGR

5 Years:
-1%
3 Years:
0%
1 Year:
-17%

Return on Equity

4 Years:
39%
Last Year:
62%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. EPS restated for bonus issues and splits. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ CrJun 2022Jun 2023Jun 2024Mar 2026
Equity Capital17171717
Reserves600734522508
Borrowings312109
269338247308
Total Liabilities8881,101794841
150173132113
CWIP4133614
698895657715
Total Assets8881,101794841

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ CrJun 2022Jun 2023Jun 2024Mar 2026
170236228338
-26-22-71
-289-98-418-344
Net Cash Flow-145116-197-5
Free Cash Flow132194207322

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

RatioJun 2022Jun 2023Jun 2024Mar 2026
ROE31.2%33.6%31.2%61.5%
ROCE38.7%39.5%47.6%76.8%
Operating margin22.7%24.5%24.7%31.4%
Net margin17.6%19.0%17.8%23.6%
Debt / equity0.000.020.020.02
Current ratio2.622.622.392.18

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities).

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

  • Promoters 51.82%
  • FIIs 6.42%
  • DIIs 12.63%
  • Public 29.13%
%Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%51.82%
7.59%6.24%6.40%6.61%7.02%6.87%6.99%7.24%6.97%6.20%6.33%6.42%
12.67%13.73%14.55%14.84%14.71%14.21%14.16%13.91%13.84%13.67%12.44%12.63%
27.92%28.21%27.23%26.74%26.46%27.11%27.03%27.04%27.37%28.31%29.42%29.13%
No. of Shareholders56,73056,77855,92354,79253,73653,99352,47850,00649,30250,88349,05650,426

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Documents

Announcements

All announcements on NSE →

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date
27 Aug 2026
Latest quarter
30 Jun 2026
Financial year end
31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an accountHow it works

Questions about Procter & Gamble Health Limited

What is the share price of Procter & Gamble Health Limited today?
Procter & Gamble Health Limited (PGHL) last traded at ₹5,200.00 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.
What is the market cap of Procter & Gamble Health Limited?
About ₹8,632 crore at the latest price.
What is the P/E ratio of Procter & Gamble Health Limited?
About 24.2 times its earnings over the last 12 months.
Is Procter & Gamble Health Limited a good investment?
We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.
How can I buy Procter & Gamble Health Limited shares?
You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.
Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).
Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

  • 100% free
  • No obligation
  • Reply within 2 hours
+91
Join 2,000+ investors who plan with Plenitude
Your details are private and never shared.
WhatsApp Book free call